Nonetheless, the present data warrant assessment of the survival benefits of curcumin analogs in humans, particularly because no inhibitors of β-catenin or STAT3 have been approved for clinical use as chemotherapeutic agents for cancer. The gene discussed is STAT3; the disease is cancer.